Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
University of California, Irvine
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
Seagen Inc.
Merus B.V.
Pfizer
Arvinas Inc.
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Genentech, Inc.
Brigham and Women's Hospital
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Amgen
Daiichi Sankyo
One-carbon Therapeutics AB
SN BioScience
Takeda
Qilu Pharmaceutical Co., Ltd.
Perspective Therapeutics
Second Life Therapeutics
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
Var2 Pharmaceuticals
GlaxoSmithKline
University of Pittsburgh
Tanabe Pharma America, Inc.
HiFiBiO Therapeutics
BicycleTx Limited
AbbVie
Actym Therapeutics, Inc.
LigaChem Biosciences, Inc.
Bolt Biotherapeutics, Inc.
Nurix Therapeutics, Inc.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Palleon Pharmaceuticals, Inc.
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Milton S. Hershey Medical Center
Incyte Corporation
NuCana plc